This is an open label extension protocol for patients who have been treated in previous ARQ 197 studies that have reached their designated end-dates. Patients enrolled in this extension protocol will receive either ARQ 197 as monotherapy or in combination with other drug(s) at the same dose(s), and same schedule(s) in which they were originally enrolled.